Clinical Trial Update: Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating KIACTA for preventing renal function decline in AA amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aa Amyloidosis

Drugs mentioned

• KIACTA

Snippet

Sponsor: C.T. Development America, Inc. | Conditions: Amyloidosis | Phase 3 | Status: COMPLETED